Tokyo, Japan

Katsukiyo Sakurai


Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 165(Granted Patents)


Company Filing History:


Years Active: 1994-1998

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations of Katsukiyo Sakurai

Introduction

Katsukiyo Sakurai is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of glycosaminoglycan derivatives, focusing on their applications in medical materials and cancer treatment. With a total of five patents to his name, Sakurai's work is characterized by its emphasis on safety and biocompatibility.

Latest Patents

Sakurai's latest patents include innovative photocurable glycosaminoglycan derivatives and crosslinked glycosaminoglycans. These inventions are designed to be highly safe and biocompatible, providing methods for preparing photocurable GAG derivatives that can be molded by casting using a solvent. This method allows for the elimination of unreacted substances that could cause adverse effects. Additionally, he has developed a metastasis inhibitor composition that links glycosaminoglycan to phospholipid or lipid, which is expected to inhibit cancer cell adhesion to blood vessel endothelial cells and extracellular matrix.

Career Highlights

Throughout his career, Sakurai has worked with notable companies such as Seikagaku Kogyo Kabushiki Kaisha and Seikagaku Corporation. His work has been instrumental in advancing the understanding and application of glycosaminoglycans in medical science.

Collaborations

Sakurai has collaborated with esteemed colleagues, including Takehisa Matsuda and Minoo J Moghaddam, to further his research and innovations in the field.

Conclusion

Katsukiyo Sakurai's contributions to the field of glycosaminoglycan derivatives highlight his commitment to innovation and safety in medical applications. His patents reflect a deep understanding of biocompatibility and the potential for significant advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…